JP7866687B2 - 置換ピペラジン誘導体の結晶およびその調製方法 - Google Patents
置換ピペラジン誘導体の結晶およびその調製方法Info
- Publication number
- JP7866687B2 JP7866687B2 JP2025525056A JP2025525056A JP7866687B2 JP 7866687 B2 JP7866687 B2 JP 7866687B2 JP 2025525056 A JP2025525056 A JP 2025525056A JP 2025525056 A JP2025525056 A JP 2025525056A JP 7866687 B2 JP7866687 B2 JP 7866687B2
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- crystal form
- diffraction pattern
- solvent
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211417721.3 | 2022-11-14 | ||
| CN202211417721 | 2022-11-14 | ||
| PCT/CN2023/131627 WO2024104354A1 (zh) | 2022-11-14 | 2023-11-14 | 一种取代的哌嗪衍生物的晶体及其制备方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025536416A JP2025536416A (ja) | 2025-11-05 |
| JP2025536416A5 JP2025536416A5 (cg-RX-API-DMAC7.html) | 2026-04-10 |
| JP7866687B2 true JP7866687B2 (ja) | 2026-05-27 |
Family
ID=90997576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025525056A Active JP7866687B2 (ja) | 2022-11-14 | 2023-11-14 | 置換ピペラジン誘導体の結晶およびその調製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250270223A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4620958A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7866687B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250086779A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118027039A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023381502A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025005591A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI879228B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024104354A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326495A (en) * | 2023-08-17 | 2026-04-01 | Kangbaida Sichuan Biotechnology Co Ltd | Pharmaceutical preparation of piperazine derivative, preparation method therefor, and use thereof |
| WO2025209574A1 (zh) * | 2024-04-03 | 2025-10-09 | 康百达(四川)生物医药科技有限公司 | 用于预防或治疗肿瘤的parp7抑制剂 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| CN112424188A (zh) | 2018-04-30 | 2021-02-26 | 里邦医疗公司 | 作为parp7抑制剂的哒嗪酮 |
| CN112745312A (zh) | 2019-10-30 | 2021-05-04 | 沈阳中化农药化工研发有限公司 | 哒嗪酮异恶唑甲醚类化合物及其应用 |
| WO2021087018A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| WO2022111700A1 (zh) | 2020-11-27 | 2022-06-02 | 成都百裕制药股份有限公司 | 哒嗪酮衍生物及其在医药上的应用 |
| WO2022156708A1 (en) | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| WO2022242750A1 (zh) | 2021-05-21 | 2022-11-24 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
-
2023
- 2023-11-14 TW TW112143895A patent/TWI879228B/zh active
- 2023-11-14 WO PCT/CN2023/131627 patent/WO2024104354A1/zh not_active Ceased
- 2023-11-14 CN CN202311526331.4A patent/CN118027039A/zh active Pending
- 2023-11-14 JP JP2025525056A patent/JP7866687B2/ja active Active
- 2023-11-14 EP EP23890787.7A patent/EP4620958A4/en active Pending
- 2023-11-14 AU AU2023381502A patent/AU2023381502A1/en active Pending
- 2023-11-14 KR KR1020257016149A patent/KR20250086779A/ko active Pending
-
2025
- 2025-05-13 MX MX2025005591A patent/MX2025005591A/es unknown
- 2025-05-13 US US19/207,109 patent/US20250270223A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112424188A (zh) | 2018-04-30 | 2021-02-26 | 里邦医疗公司 | 作为parp7抑制剂的哒嗪酮 |
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| CN112745312A (zh) | 2019-10-30 | 2021-05-04 | 沈阳中化农药化工研发有限公司 | 哒嗪酮异恶唑甲醚类化合物及其应用 |
| WO2021087018A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| WO2022111700A1 (zh) | 2020-11-27 | 2022-06-02 | 成都百裕制药股份有限公司 | 哒嗪酮衍生物及其在医药上的应用 |
| WO2022156708A1 (en) | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| WO2022242750A1 (zh) | 2021-05-21 | 2022-11-24 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4620958A1 (en) | 2025-09-24 |
| TWI879228B (zh) | 2025-04-01 |
| JP2025536416A (ja) | 2025-11-05 |
| AU2023381502A1 (en) | 2025-05-15 |
| US20250270223A1 (en) | 2025-08-28 |
| EP4620958A4 (en) | 2026-08-05 |
| KR20250086779A (ko) | 2025-06-13 |
| MX2025005591A (es) | 2025-06-02 |
| TW202426452A (zh) | 2024-07-01 |
| CN118027039A (zh) | 2024-05-14 |
| WO2024104354A1 (zh) | 2024-05-23 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250530 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20260402 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260421 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260515 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7866687 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |